From September to December 2020, over 130 contributors from 16 countries across Europe2 came together in a bottom-up process3 to collect and discuss basic principles for successful patient involvement. They represented patient organizations, cancer research, participatory research, medical and healthcare professions, industry, research management, funding organizations and the policy-making level.
From September to December 2020, over 130 contributors from 16 countries across Europe2 came together in a bottom-up process3 to collect and discuss basic principles for successful patient involvement. They represented patient organizations, cancer research, participatory research, medical and healthcare professions, industry, research management, funding organizations and the policy-making level.
A síndrome de Lynch é uma das síndromes hereditárias de predisposição para cancro mais comuns. Trata-se de uma doença com transmissão autossómica dominante que surge após uma mutação germinativa num dos genes envolvidos na reparação do ADN: MLH1, MSH2, MSH6 e PMS2. Os indivíduos afetados apresentam um risco acrescido para cancro colorretal e outros cancros extracólicos, nomeadamente endométrio, ovário, estômago, intestino delgado, trato urinário, pâncreas e outros tumores cerebrais ou de glândulas.
The capacity to distinguish tumors that will benefit from anti-cancer treatments from those that will not remains a challenge. Patient-derived xenografts (PDXs), also called “avatars,” are generated by the implantation of human primary tumor cells or tissues into a host animal.
Many PDX models have been developed to be used as a platform for drug screening in cancer research and precision medicine, mainly using mouse models. However, mouse models require a long time for tumor growth, which is not compatible with first clinical decisions.
A capacidade de distinguir os tumores que beneficiarão de determinado tratamento anti-cancerígeno daqueles que não beneficiarão, continua a ser um desafio nos dias de hoje. Os xenografos derivados do paciente (PDXs), também chamados de “Avatars”, são gerados pela implantação de células ou tecidos tumorais de humanos num animal hospedeiro.
